CS/CS/HB 1617 creates new Florida statutes governing stem cell therapy performed by licensed allopathic and osteopathic physicians. The bill allows physicians to provide certain stem cell therapies that have not been approved by the U.S. Food and Drug Administration, but only for treatments within the physician’s scope of practice and only in the areas of orthopedics, wound care, or pain management. It defines key terms, excludes treatments involving fetal or embryonic tissue after abortion, and expresses legislative intent to promote regenerative medicine while requiring ethically sourced stem cells, including adult stem cells and umbilical cord blood.
The bill imposes detailed sourcing, manufacturing, and documentation requirements. Stem cells must be produced in FDA-certified clean-room conditions, retrieved and stored in facilities registered with the FDA and accredited by specified organizations, and accompanied by post-thaw viability analysis. Physicians must ensure contracts with suppliers include certification details and notice of any change in status. The bill also requires prominent advertising disclosures stating the therapy is not FDA-approved and mandates informed consent forms that explain the treatment, risks, alternatives, and the recommendation to consult a primary care provider. It exempts certain FDA-approved investigational uses and therapies performed under specified accredited institutions, and it authorizes disciplinary action for violations while directing the relevant boards to adopt rules.
The bill’s impact on state law is to create a new regulatory framework for stem cell therapy in Florida for both medical and osteopathic physicians. It does not broadly authorize all stem cell uses; instead, it narrows permissible practice to specified clinical contexts and ties legality to compliance with state and federal manufacturing, storage, advertising, and consent standards. It also gives the Board of Medicine and Board of Osteopathic Medicine enforcement and rulemaking authority, which could affect physicians, clinics, tissue banks, and other entities involved in sourcing or marketing stem cell products.
The general sentiment reflected in the committee votes appears strongly favorable, with unanimous approval in both the House Health Professions & Programs Subcommittee and the House Health & Human Services Committee. The bill’s framing suggests support for medical innovation, patient access, and ethical safeguards, and the lack of recorded opposition in the available vote history indicates broad committee agreement.
The main points of contention likely center on the bill’s ethical restrictions and its allowance of non-FDA-approved therapies. Supporters emphasize the prohibition on fetal-derived stem cells and the requirement for informed consent and quality controls, while potential critics may question whether permitting unapproved therapies could create patient-safety or efficacy concerns despite the added safeguards. Another possible area of debate is the bill’s narrow scope, which favors certain stem cell sources and treatment areas while excluding others such as adipose-derived mesenchymal stem cells for transplantation.
Creates new sections 458.3245 and 459.0127, Florida Statutes, regulating stem cell therapy by licensed physicians and osteopathic physicians. It authorizes certain non-FDA-approved stem cell therapies in limited practice areas, imposes sourcing, manufacturing, advertising, and informed-consent requirements, provides exemptions for FDA-approved investigational uses and certain accredited institutions, and subjects violations to professional discipline. The bill also requires rulemaking by the Board of Medicine and Board of Osteopathic Medicine.
Committee action was uniformly positive, with unanimous votes in both committees listed and no recorded dissent. The bill is presented as a pro-innovation measure with ethical guardrails, and the available history suggests broad support for allowing limited stem cell therapies under strict regulation.
The likely debate is between supporters who view the bill as a way to expand access to regenerative medicine while preventing unethical sourcing, and skeptics who may worry that authorizing non-FDA-approved therapies could expose patients to unproven treatments. The bill also draws a clear line against fetal-derived stem cells and excludes some stem cell types, which may be welcomed by some stakeholders but criticized by others who favor a broader therapeutic framework.